Korsana Biosciences, Inc.(KRSA)

Biotechnology · Waltham, MA

$31.77+1.05 (+3.42%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T21:02:20.069Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:02:20.069Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 148,726,490
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 1,391,000
TTM operating EBITDA · period ending 2026-06-30: -6,824,000

FMP input reference: a391670e5a4a022aad0cee8204cefb21b4613c0a4e77d467850b61b24c11a6b7

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KRSA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

KRSA Competitors' EV/EBITDA Ratio

KRSA

Korsana Biosciences, Inc.

Current

Market Cap

$148.73M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VYGR

Voyager Therapeutics, Inc.

vs KRSA

Market Cap

$148.64M

EV/EBITDA Ratio

N/A

TTM Avg

11.98x

3Y Avg

6.17x

5Y Avg

5.29x

AVXL

Anavex Life Sciences Corp.

vs KRSA

Market Cap

$148.27M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALXO

ALX Oncology Holdings Inc.

vs KRSA

Market Cap

$149.36M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABOS

Acumen Pharmaceuticals, Inc.

vs KRSA

Market Cap

$146.62M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRDL

Cardiol Therapeutics Inc.

vs KRSA

Market Cap

$151.01M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDXS

Codexis, Inc.

vs KRSA

Market Cap

$146.28M

EV/EBITDA Ratio

N/A

TTM Avg

183.85x

3Y Avg

184.46x

5Y Avg

184.46x

FBIOP

Fortress Biotech, Inc.

vs KRSA

Market Cap

$146.27M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VRXA

Veraxa Biotech Holding AG

vs KRSA

Market Cap

$152.72M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MENS

Jyong Biotech Ltd. Ordinary Shares

vs KRSA

Market Cap

$153.58M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Korsana Biosciences, Inc. (KRSA)	$148.73M	N/A	N/A	N/A	N/A
Voyager Therapeutics, Inc. (VYGR)vs ›	$148.64M	N/A	11.98x	6.17x	5.29x
Anavex Life Sciences Corp. (AVXL)vs ›	$148.27M	N/A	N/A	N/A	N/A
ALX Oncology Holdings Inc. (ALXO)vs ›	$149.36M	N/A	N/A	N/A	N/A
Acumen Pharmaceuticals, Inc. (ABOS)vs ›	$146.62M	N/A	N/A	N/A	N/A
Cardiol Therapeutics Inc. (CRDL)vs ›	$151.01M	N/A	N/A	N/A	N/A
Codexis, Inc. (CDXS)vs ›	$146.28M	N/A	183.85x	184.46x	184.46x
Fortress Biotech, Inc. (FBIOP)vs ›	$146.27M	N/A	N/A	N/A	N/A
Veraxa Biotech Holding AG (VRXA)vs ›	$152.72M	N/A	N/A	N/A	N/A
Jyong Biotech Ltd. Ordinary Shares (MENS)vs ›	$153.58M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics